Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 12/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110988 | 1.00 | TRPV4 (0.39) | TRPV4EGFRACSS2ACACBMAT2A | |
| SCHEMBL18791989 | 1.00 | TRPV4 (0.39) | TRPV4EGFRACSS2ACACBMAT2A | |
| SCHEMBL18791999 | 0.90 | EGFR (0.37) | TRPV4EGFRACSS2MAP3K7IRAK4 | |
| SCHEMBL18792006 | 0.90 | EGFR (0.37) | TRPV4EGFRACSS2MAP3K7IRAK4 | |
| SCHEMBL20110984 | 0.90 | EGFR (0.37) | TRPV4EGFRACSS2MAP3K7IRAK4 | |
| SCHEMBL18779274 | 0.88 | ACACB (0.39) | TRPV4ACACB | |
| SCHEMBL18791860 | 0.83 | TRPV4 (0.35) | TRPV4EGFRACACB | |
| SCHEMBL18779277 | 0.82 | TRPV4 (0.35) | TRPV4EGFRACACB | |
| SCHEMBL18791657 | 0.81 | EGFR (0.38) | TRPV4EGFRACSS2MAP3K7IRAK4 | |
| SCHEMBL18791655 | 0.81 | EGFR (0.38) | TRPV4EGFRACSS2MAP3K7IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | TRPV4 97/4885EGFR 4338/4885ACSS2 2521/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | TRPV4 104/4885EGFR 4329/4885ACSS2 928/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | TRPV4 104/4885EGFR 4329/4885ACSS2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.